Thrombolytic activity of defibrotide against old venous thrombi.
The age of the thrombus is probably a very important determinant of the outcome of thrombolysis. The clinical potential for rapidly dissolving thrombi by thrombolytic therapy is considerable because restoration of the blood flow can rescue the jeopardized district served by the occluded vessel such as for myocardial infarction, deep vein thrombosis, arterial thrombosis, pulmonary embolism, and occlusion of retinal vessels. Defibrotide was effective against 3-, 7-, or 10-day-old thrombi; its ED50s were 32, 65, or 118 mg/kg-1 hour-1, respectively, suggesting that the age of the thrombus could play a role in the outcome of thrombolysis. A similar pattern was also shown for urokinase.
Niada
R
R
Crinos Biological Research Laboratories, Como, Italy.
Porta
R
R
Pescador
R
R
Mantovani
M
M
Prino
G
G
D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D008297:Male; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*; D011817:Rabbits; D013924:Thrombophlebitis / Q000188:drug therapy*; D013988:Ticlopidine / Q000627:therapeutic use; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D006493:Heparin; D011464:Epoprostenol; D014568:Urokinase-Type Plasminogen Activator; D013988:Ticlopidine